• Silexion outlined SIL204, an siRNA designed to silence KRAS gene expression with dual delivery targeting primary pancreatic tumors and micrometastases.
• Program focus is locally advanced pancreatic cancer; KRAS mutations cited in 92% of cases, with SIL204 targeting more than 74% of PDAC KRAS mutations.
• Total addressable market estimate for localized advanced pancreatic cancer: U.S. about USD 2 billion; E.U. about USD 3 billion.
• Phase 2/3 trial plan: safety run-in to start mid-2026 with completion expected in Q2 2027; Phase 2 expansion to start Q3 2027.
• Phase 3 confirmatory segment targeted to start Q3 2030; interim results flagged for 2028 with potential sample size adjustment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.